Infectious Disease Phase 3 Readout Calendar
Industry-sponsored infectious disease trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularRare DiseaseRespiratoryInfectious DiseaseOphthalmologyMusculoskeletalDermatologyRenal
13
Next 6 months
20
Next 12 months
26
Results posted
140
Phase 3 Infectious Disease
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 infectious disease trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What infectious disease trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 infectious disease trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which infectious disease trials have already read out?
The "recently read out" section shows Phase 3 infectious disease trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Infectious Disease slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Infectious Disease landscape →
Recently read out & awaiting topline — Infectious Disease
· 11Phase 3 infectious disease trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Mundipharma Research Limited | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection | Candidemia +9 | Completed | Q1 2026 2026-01-29 | Completed · awaiting
Updated 5mo ago
| NCT04368559 |
| F2G Biotech GmbH | Olorofim Aspergillus Infection Study Asset: Olorofim | Invasive Aspergillosis | Active Not Recruiting | Q4 2025 2025-11-18 | Completed · awaiting
Updated 8mo ago
| NCT05101187 |
| ModernaTX, Inc. | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age Asset: mRNA-1083 | COVID-19 +1 | Completed | Q4 2025 2025-11-17 | Completed · awaiting
Updated 10mo ago
| NCT06694389 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Completed | Q4 2025 2025-11-11 | Completed · awaiting
Updated 9mo ago
| NCT05630807 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Completed | Q4 2025 2025-11-03 | Completed · awaiting
Updated 9mo ago
| NCT05630820 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Asset: Bictegravir | HIV-1-infection | Active Not Recruiting | Q4 2025 2025-10-27 | Completed · awaiting
Updated 10mo ago
| NCT06333808 |
| ModernaTX, Inc. | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age Asset: mRNA-1273.214 | SARS-CoV-2 | Completed | Q4 2025 2025-10-20 | Completed · awaiting
Updated 10mo ago
| NCT05436834 |
| Merck Sharp & Dohme LLC | A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) Asset: DOR/ISL | HIV Infection | Active Not Recruiting | Q4 2025 2025-10-16 | Completed · awaiting
Updated 9mo ago
| NCT05766501 |
| Merck Sharp & Dohme LLC | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) Asset: DOR/ISL | HIV-1 Infection | Active Not Recruiting | Q4 2025 2025-10-13 | Completed · awaiting
Updated 11mo ago
| NCT05705349 |
| Pfizer | A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults Asset: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Respiratory Syncytial Virus (RSV) | Completed | Q3 2025 2025-09-30 | Completed · awaiting
Updated 10mo ago
| NCT06890416 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Asset: Bictegravir | HIV-1-infection | Active Not Recruiting | Q3 2025 2025-09-29 | Completed · awaiting
Updated 11mo ago
| NCT05502341 |
Upcoming infectious disease readouts — next 12 months
· 20Industry Phase 3 infectious disease trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study Asset: RSVPreF3 OA vaccine | Respiratory Syncytial Virus Infections | Active Not Recruiting | Q3 2026 2026-09-30 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06534892 |
| Atea Pharmaceuticals, Inc. | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Asset: Bemnifosbuvir-Ruzasvir (BEM/RZR) | HEPATITIS C VIRUS CHRONIC INFECTION | Active Not Recruiting | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT06868264 |
| Beijing Continent Pharmaceutical C… | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis Asset: Hydronidone Capsules | Chronic Hepatitis B With Hepatic Fibrosis | Completed | Q4 2026 2026-10-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07343778 |
| Seqirus | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age Asset: aQIV or aTIV | Influenza, Human | Completed | Q4 2026 2026-11 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06087640 |
| LG Chem | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series Asset: LBVD | Diphtheria +5 | Active Not Recruiting | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 15mo ago
| NCT06947499 |
Unlock 15 more infectious disease readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.